Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
Soncini D, Becherini P, Ladisa F, Ravera S, Chedere A, Gelli E, Giorgetti G, Martinuzzi C, Piacente F Dr, Mastracci L, Veneziano C Dr, Santamaria G Dr, Monacelli F, Ghanem MS, Cagnetta A, Guolo F Dr, Garibotto M, Aquino S, Passalacqua M, Bruzzone S, Bellotti A, Duchosal MA, Nahimana AA, Angelucci E, Nagasuma C Prof, Nencioni A, Lemoli RM, Cea M Prof. Soncini D, et al. Among authors: ravera s. Blood Adv. 2024 Dec 11:bloodadvances.2024013425. doi: 10.1182/bloodadvances.2024013425. Online ahead of print. Blood Adv. 2024. PMID: 39661983
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal M, Bruzzone S, Nencioni A. Piacente F, et al. Among authors: ravera s. Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15. Cancer Res. 2017. PMID: 28507103
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem MS, Caffa I, Del Rio A, Franco J, Parenti MD, Monacelli F, Cea M, Khalifa A, Nahimana A, Duchosal MA, Ravera S, Bertola N, Bruzzone S, Nencioni A, Piacente F. Ghanem MS, et al. Among authors: ravera s. Pharmaceuticals (Basel). 2022 Jul 10;15(7):848. doi: 10.3390/ph15070848. Pharmaceuticals (Basel). 2022. PMID: 35890147 Free PMC article.
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents.
Becherini P, Soncini D, Ravera S, Gelli E, Martinuzzi C, Giorgetti G, Cagnetta A, Guolo F, Ivaldi F, Miglino M, Aquino S, Todoerti K, Neri A, Benzi A, Passalacqua M, Nencioni A, Perrotta I, Gallo Cantafio ME, Amodio N, De Flora A, Bruzzone S, Lemoli RM, Cea M. Becherini P, et al. Among authors: ravera s. Antioxidants (Basel). 2023 Feb 15;12(2):494. doi: 10.3390/antiox12020494. Antioxidants (Basel). 2023. PMID: 36830052 Free PMC article.
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice.
Becherini P, Caffa I, Piacente F, Damonte P, Vellone VG, Passalacqua M, Benzi A, Bonfiglio T, Reverberi D, Khalifa A, Ghanem M, Guijarro A, Tagliafico L, Sucameli M, Persia A, Monacelli F, Cea M, Bruzzone S, Ravera S, Nencioni A. Becherini P, et al. Among authors: ravera s. Cancer Metab. 2021 Jan 22;9(1):6. doi: 10.1186/s40170-021-00240-1. Cancer Metab. 2021. PMID: 33482921 Free PMC article.
Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model.
Sociali G, Magnone M, Ravera S, Damonte P, Vigliarolo T, Von Holtey M, Vellone VG, Millo E, Caffa I, Cea M, Parenti MD, Del Rio A, Murone M, Mostoslavsky R, Grozio A, Nencioni A, Bruzzone S. Sociali G, et al. Among authors: ravera s. FASEB J. 2017 Jul;31(7):3138-3149. doi: 10.1096/fj.201601294R. Epub 2017 Apr 6. FASEB J. 2017. PMID: 28386046 Free PMC article.
This study represents the first in vivo study of a SIRT6 inhibitor and provides the proof-of-concept that targeting SIRT6 may be a viable strategy for improving glycemic control in T2DM.-Sociali, G., Magnone, M., Ravera, S., Damonte, P., Vigliarolo, T., Von Holtey, …
This study represents the first in vivo study of a SIRT6 inhibitor and provides the proof-of-concept that targeting SIRT6 may be a viable st …
Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells.
Salani B, Ravera S, Fabbi P, Garibaldi S, Passalacqua M, Brunelli C, Maggi D, Cordera R, Ameri P. Salani B, et al. Among authors: ravera s. Cell Physiol Biochem. 2017;43(3):879-890. doi: 10.1159/000481638. Epub 2017 Sep 28. Cell Physiol Biochem. 2017. PMID: 28954268 Free article.
273 results